drugset
drugset / Trial / NCT04119674

Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma

NCT04119674 ↗

Phase 1/2 Completed 33 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the the efficacy and safety of Anlotinib in combination with STUPP regimen for patients with newly diagnosed glioblastoma.

Timeline

Start
2019-03-19
Primary completion
2022-08-23
Completion
2022-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 8 mg Oral
Subject Temozolomide Small molecule 200 mg/m2 —

Indications

glioblastoma